Overview

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Status:
Recruiting

Trial end date:
2024-11-15

Target enrollment:

Participant gender:

Summary

To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Lenvatinib